Edgewise Therapeutics Inc EWTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
-
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
-
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
-
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
-
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
-
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Trading Information
- Previous Close Price
- $34.06
- Day Range
- $32.50–34.70
- 52-Week Range
- $12.15–40.77
- Bid/Ask
- $32.30 / $36.90
- Shares Outstanding
- 107.59M
- Market Cap
- $3.54B
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 154
- Website
- https://www.edgewisetx.com
Valuation
|
Metric
|
EWTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.42 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EWTX
|
|---|---|
Quick Ratio | 22.16 |
Current Ratio | 22.61 |
Interest Coverage | — |
Quick Ratio
EWTX
Profitability
|
Metric
|
EWTX
|
|---|---|
Return on Assets (Normalized) | −26.01% |
Return on Equity (Normalized) | −27.31% |
Return on Invested Capital (Normalized) | −31.59% |
Return on Assets
EWTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Sljlptpc | Svlbx | $111B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Knfsmdr | Rtcklc | $63B | |||
| argenx SE ADR
ARGX
| Qtkwyvlt | Nbgzm | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xwscwqd | Djvcvd | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Txdvwmmk | Gxzdrcq | $25B | |||
| BioNTech SE ADR
BNTX
| Nwjvhhlng | Nnfy | $22B | |||
| Incyte Corp
INCY
| Bjxnntgs | Pxls | $21B | |||
| Moderna Inc
MRNA
| Btcvtmvby | Zrx | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Mdwjskfd | Hgsgf | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Kvytjlws | Yxc | $13B |
United States